id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-P-0346-0007,FDA,FDA-2003-P-0346,"Reclassification Petition from Beckman Coulter, Inc.",Other,CCP-Change in Classification Petition,2008-11-17T05:00:00Z,2008,11,2008-11-17T05:00:00Z,,2024-11-25T17:08:50Z,,0,0,0900006480496dfc
FDA-2003-P-0346-0004,FDA,FDA-2003-P-0346,"Final Rule; Correction Re: Microbiology Devices; Reclassification of Hepatitis, A Virus Serological Assays; Correction",Rule,NCR-Notice of Correction,2006-03-03T05:00:00Z,2006,3,2006-02-28T05:00:00Z,2006-05-02T03:59:59Z,2024-11-25T16:50:04Z,71FR10433,0,0,0900006480496e10
FDA-2003-P-0346-0003,FDA,FDA-2003-P-0346,"Final Rule Re: Microbiology Devices; Reclassification of Hepatitis, A Virus Serological Assays",Rule,NFR-Notice of Final Rule,2006-02-10T05:00:00Z,2006,2,2006-02-08T05:00:00Z,2006-02-10T04:59:59Z,2024-11-25T16:45:55Z,71FR6677,0,0,0900006480496e0e
FDA-2003-P-0346-0002,FDA,FDA-2003-P-0346,"Proposed Rule re Microbiology Devices; Reclassification of Hepatitis A Virus (HAV) Serological Assays (IgM Antibody, IgG Antibody and Total Antibodies [IgM and IgG])",Proposed Rule,NPR-Notice of Proposed Rule-Making,2004-09-30T04:00:00Z,2004,9,2004-09-29T04:00:00Z,2004-12-30T04:59:59Z,2024-11-25T16:34:43Z,69FR58371,0,0,0900006480496e02
FDA-2003-P-0346-0001,FDA,FDA-2003-P-0346,"Acknowledgement Letter from FDA DMB to Beckman Coulter, Inc.",Other,Acknowledgement Letter/Receipt,2003-12-16T05:00:00Z,2003,12,2003-12-16T05:00:00Z,,2024-11-25T16:27:06Z,,0,0,0900006480496db0